Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. In collaboration with AbbVie, Janssen, and Schrödinger, Morphic is advancing its pipeline and discovery activities using its proprietary MInT technology platform which leverages Morphic's unique understanding of integrin structure and biology.
Company profile
Ticker
MORF
Exchange
Website
CEO
Praveen P. Tipirneni
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Morphic Holding, LLC
SEC CIK
Corporate docs
Subsidiaries
Morphic Therapeutic, Inc. • Morphic Security Corporation ...
IRS number
473878772
MORF stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Termination of a Material Definitive Agreement
20 Jan 23
10-Q
2022 Q3
Quarterly report
2 Nov 22
8-K
Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2022
2 Nov 22
8-K
Morphic Announces Complete Enrollment of EMERALD-1 Main Cohort Ahead of Projections
24 Oct 22
10-Q
2022 Q2
Quarterly report
3 Aug 22
8-K
Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2022
3 Aug 22
8-K
Termination of a Material Definitive Agreement
21 Jun 22
8-K
Submission of Matters to a Vote of Security Holders
9 Jun 22
8-K
Morphic Names Bruce Rogers as President of Morphic Therapeutic and Blaise Lippa as Chief Scientific Officer
12 May 22
10-Q
2022 Q1
Quarterly report
4 May 22
Transcripts
Latest ownership filings
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|
| Revenue | ||||
| Cost of revenue | ||||
| Operating income | ||||
| Operating margin | ||||
| Net income | ||||
| Net profit margin | ||||
| Cash on hand | ||||
| Change in cash | ||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 85.52 mm | 85.52 mm | 85.52 mm | 85.52 mm | 85.52 mm | 85.52 mm |
| Cash burn (monthly) | 18.74 mm | 8.27 mm | 10.50 mm | 4.82 mm | 8.30 mm | 8.04 mm |
| Cash used (since last report) | 78.48 mm | 34.62 mm | 43.96 mm | 20.19 mm | 34.75 mm | 33.66 mm |
| Cash remaining | 7.04 mm | 50.90 mm | 41.56 mm | 65.33 mm | 50.77 mm | 51.86 mm |
| Runway (months of cash) | 0.4 | 6.2 | 4.0 | 13.5 | 6.1 | 6.5 |
Institutional ownership, Q3 2022
88.6% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 114 |
| Opened positions | 23 |
| Closed positions | 11 |
| Increased positions | 46 |
| Reduced positions | 26 |
| 13F shares | Current |
|---|---|
| Total value | 1.06 bn |
| Total shares | 34.14 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| FMR | 5.77 mm | $163.34 mm |
| EcoR1 Capital | 3.95 mm | $111.83 mm |
| Artal | 2.15 mm | $60.85 mm |
| Polaris Partners VII | 2.09 mm | $99.06 mm |
| BLK Blackrock | 1.95 mm | $55.08 mm |
| Artal International S.C.A. | 1.59 mm | $75.10 mm |
| Vanguard | 1.45 mm | $41.08 mm |
| Wellington Management | 1.34 mm | $38.01 mm |
| Holocene Advisors | 1.22 mm | $34.62 mm |
| Omega Fund V | 1.20 mm | $56.86 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 14 Jan 23 | Praveen P. Tipirneni | Common Stock | Sell | Dispose S | No | No | 30.6277 | 4,027 | 123.34 k | 12,679 |
| 14 Jan 23 | Praveen P. Tipirneni | Common Stock | Option exercise | Acquire M | No | No | 0 | 12,500 | 0.00 | 16,706 |
| 14 Jan 23 | Praveen P. Tipirneni | RSU Common Stock | Option exercise | Acquire M | No | No | 0 | 12,500 | 0.00 | 37,500 |
| 14 Jan 23 | Schegerin Marc | Common Stock | Sell | Dispose S | No | No | 30.6286 | 1,670 | 51.15 k | 16,212 |
| 14 Jan 23 | Schegerin Marc | Common Stock | Option exercise | Acquire M | No | No | 0 | 4,690 | 0.00 | 17,882 |
| 14 Jan 23 | Schegerin Marc | RSU Common Stock | Option exercise | Acquire M | No | No | 0 | 4,690 | 0.00 | 14,070 |
| 14 Jan 23 | Rogers Bruce | Common Stock | Sell | Dispose S | No | No | 30.6289 | 1,778 | 54.46 k | 116,192 |
| 14 Jan 23 | Rogers Bruce | Common Stock | Option exercise | Acquire M | No | No | 0 | 5,070 | 0.00 | 117,970 |
| 14 Jan 23 | Rogers Bruce | RSU Common Stock | Option exercise | Acquire M | No | No | 0 | 5,070 | 0.00 | 15,210 |
| 14 Jan 23 | DeVaul William | Common Stock | Sell | Dispose S | No | No | 30.6284 | 1,169 | 35.80 k | 23,739 |